Analyst Update: Potash Corp, Conatus Pharma, Horizon Pharma

Analysts adjusted their ratings on Potash Corp./Saskatchewan (USA) (POT), Conatus Pharmaceuticals Inc (CNAT), and Horizon Pharma PLC (HZNP)

Sep 22, 2015 at 12:59 PM
facebook twitter linkedin



Analysts chimed in on fertilizer producer Potash Corp./Saskatchewan (USA) (NYSE:POT), as well as biotechnology concerns Conatus Pharmaceuticals Inc (NASDAQ:CNAT) and Horizon Pharma PLC (NASDAQ:HZNP).  Here's a quick roundup of today's brokerage notes on POT, CNAT, and HZNP.

  • CNAT is 9.2% higher at $4.74, bucking the broad-market trend, after H.C. Wainwright started the stock with a "buy" rating and a $15 price target -- more than three times the stock's current price. The brokerage firm attributed the upbeat opinion to the prospects for emricasan, CNAT's liver drug. On Aug. 26, shares of Conatus Pharmaceuticals Inc hit a record low of $3.44, but have bounced back, adding roughly 21% in September alone. What's more, today's rally has the stock trading above its 80-day moving average for the first time since June. 
  • Finally, HZNP is headed in the opposite direction of its sector mate CNAT, dropping 12.5% to $25.38. Horizon Pharma PLC dropped after Brean cut the equity to "hold" from "buy," citing "unsettling" developments -- including the belief that a Depomed (NASDAQ:DEPO) deal won't happen. Despite today's drop, HZNP has almost doubled in 2015, but is in danger of breaching its 200-day moving average for the first time this year. Should the stock continue to fall, there could be some pressure from downgrades, as all seven of the brokerages rating HZNP feel it worthy of a "buy" or better.
For other stocks in analysts' crosshairs, read Analyst Upgrades: Halozyme Therapeutics, Inc., Nike Inc, and EMC Corporation and Analyst Downgrades: Red Hat Inc, Caterpillar Inc., and Mosaic Co
 

 

 

These investors are using market volatility to their advantage and scoring triple-digit gains on many of their trades.

Even in today's sideways bear market, this trading strategy has continued to provide consistency and profitability to a small group of investors. By using this approach, these traders are removing directional risk and still hitting triple-digit returns. If you want access to this strategy, and lower risk with higher returns sounds good to you, then don't wait another minute.

Join us now to receive our next trades the moment they come out!

Common mistakes options traders make
 


 


 
Special Offers from Schaeffer's Trading Partners